NCT02620800 - Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2016

Primary Completion Date

October 29, 2018

Study Completion Date

October 29, 2018

Conditions

Metastatic Pancreas Adenocarcinoma

Interventions

DRUG

5FU

5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump

DRUG

nab-paclitaxel

nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15

DRUG

bevacizumab

bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15

DRUG

calcium leucovorin

calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15

DRUG

oxaliplatin

oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15

Trial Locations (7)

Cornell University Weill Medical College, New York

Gibbs Cancer Center and Research Institute, Spartanburg

University of Michigan, Ann Arbor

Karmanos Cancer Center Wayne State University, Detroit

Northwestern University, Chicago

Virginia Mason Cancer Center, Seattle

Tufts - New England Medical Center, Boston